In December 2022, the US biotech firm Moderna, a company that emerged from relative obscurity to become a household name during the pandemic, published the results of a clinical trial that sent ripples through the world of cancer research.
Conducted in partnership with the pharma company MSD, it demonstrated that a messenger RNA (mRNA) cancer vaccine, used in combination with immunotherapy, could offer significant benefit to patients with advanced melanoma who had received surgery to remove their tumours. After a year’s worth of treatment, the phase IIb trial found that the combination reduced the risk of cancer recurrence or death by 44%.
